AU611204B2 - Treatment of lipoprotein disorders associated with cholesterol metabolism - Google Patents
Treatment of lipoprotein disorders associated with cholesterol metabolism Download PDFInfo
- Publication number
- AU611204B2 AU611204B2 AU23433/88A AU2343388A AU611204B2 AU 611204 B2 AU611204 B2 AU 611204B2 AU 23433/88 A AU23433/88 A AU 23433/88A AU 2343388 A AU2343388 A AU 2343388A AU 611204 B2 AU611204 B2 AU 611204B2
- Authority
- AU
- Australia
- Prior art keywords
- blackcurrant
- cholesterol
- composition
- disorders associated
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 36
- 102000004895 Lipoproteins Human genes 0.000 title claims abstract description 12
- 108090001030 Lipoproteins Proteins 0.000 title claims abstract description 12
- 230000004060 metabolic process Effects 0.000 title claims abstract description 8
- 239000010473 blackcurrant seed oil Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 11
- 235000001466 Ribes nigrum Nutrition 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 10
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- 240000001890 Ribes hudsonianum Species 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 239000008169 grapeseed oil Substances 0.000 description 9
- 241001312569 Ribes nigrum Species 0.000 description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 4
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 3
- 229960002733 gamolenic acid Drugs 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 208000034599 Dysbetalipoproteinemia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- 206010060755 Type V hyperlipidaemia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940094199 black currant oil Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- QWUFXJHVFNRNCU-UHFFFAOYSA-N phenazin-1-amine Chemical compound C1=CC=C2N=C3C(N)=CC=CC3=NC2=C1 QWUFXJHVFNRNCU-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH4069/87 | 1987-10-16 | ||
| CH4069/87A CH673223A5 (enrdf_load_stackoverflow) | 1987-10-16 | 1987-10-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2343388A AU2343388A (en) | 1989-04-20 |
| AU611204B2 true AU611204B2 (en) | 1991-06-06 |
Family
ID=4269238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU23433/88A Ceased AU611204B2 (en) | 1987-10-16 | 1988-10-05 | Treatment of lipoprotein disorders associated with cholesterol metabolism |
Country Status (10)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6325289U (enrdf_load_stackoverflow) * | 1986-07-31 | 1988-02-19 | ||
| CH676909A5 (enrdf_load_stackoverflow) * | 1988-12-23 | 1991-03-28 | Nestle Sa | |
| JP2917037B2 (ja) * | 1990-01-09 | 1999-07-12 | 株式会社アドバンス | Ａｃａｔ阻害剤 |
| US6667064B2 (en) * | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
| JP2006014730A (ja) * | 2004-05-31 | 2006-01-19 | Toyo Shinyaku:Kk | 食品 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU555940B2 (en) * | 1982-04-16 | 1986-10-16 | Societe Des Produits Nestle S.A. | Compositions containing fatty substances |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2834227A1 (de) * | 1978-08-04 | 1980-02-28 | Merck Patent Gmbh | Hypo- beta -lipoproteinaemisches diaetetikum, verfahren zu seiner herstellung und verwendung |
| JPS61118318A (ja) * | 1984-11-12 | 1986-06-05 | Pola Chem Ind Inc | 血清脂質改善用組成物 |
-
1987
- 1987-10-16 CH CH4069/87A patent/CH673223A5/fr not_active IP Right Cessation
-
1988
- 1988-10-03 AT AT88116343T patent/ATE72987T1/de not_active IP Right Cessation
- 1988-10-03 EP EP88116343A patent/EP0311866B1/fr not_active Expired - Lifetime
- 1988-10-03 ES ES198888116343T patent/ES2036650T3/es not_active Expired - Lifetime
- 1988-10-03 DE DE8888116343T patent/DE3868827D1/de not_active Expired - Fee Related
- 1988-10-03 IE IE298988A patent/IE61682B1/en not_active IP Right Cessation
- 1988-10-05 AU AU23433/88A patent/AU611204B2/en not_active Ceased
- 1988-10-14 CA CA000580218A patent/CA1314229C/en not_active Expired - Fee Related
- 1988-10-14 JP JP63257453A patent/JPH075471B2/ja not_active Expired - Lifetime
-
1992
- 1992-03-05 GR GR920400345T patent/GR3003990T3/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU555940B2 (en) * | 1982-04-16 | 1986-10-16 | Societe Des Produits Nestle S.A. | Compositions containing fatty substances |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH075471B2 (ja) | 1995-01-25 |
| JPH01132530A (ja) | 1989-05-25 |
| EP0311866A1 (fr) | 1989-04-19 |
| IE882989L (en) | 1989-04-16 |
| CA1314229C (en) | 1993-03-09 |
| AU2343388A (en) | 1989-04-20 |
| DE3868827D1 (de) | 1992-04-09 |
| EP0311866B1 (fr) | 1992-03-04 |
| ES2036650T3 (es) | 1993-06-01 |
| CH673223A5 (enrdf_load_stackoverflow) | 1990-02-28 |
| GR3003990T3 (enrdf_load_stackoverflow) | 1993-03-16 |
| ATE72987T1 (de) | 1992-03-15 |
| IE61682B1 (en) | 1994-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Childs et al. | The contrasting effects of a dietary soya lecithin product and corn oil on lipoprotein lipids in normolipidemic and familial hypercholesterolemic subjects | |
| Lieber et al. | Ethanol and lipids | |
| Beil et al. | Studies on plasma lipoproteins during absorption of exogenous lecithin in man. | |
| Leigh-Firbank et al. | Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses | |
| Tonstad et al. | The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia | |
| Nissinen et al. | Micellar distribution of cholesterol and phytosterols after duodenal plant stanol ester infusion | |
| PAUL et al. | On the mechanism of hypocholesterolemic effects of polyunsaturated lipids | |
| Greten et al. | The effect of polyunsaturated phosphatidylcholine on plasma lipids and fecal sterol excretion | |
| Hamazaki et al. | Docosahexaenoic acid-rich fish oil does not affect serum lipid concentrations of normolipidemic young adults | |
| AU2009200897A1 (en) | Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides | |
| Patton et al. | Utilization of individual lecithins in intestinal lipoprotein formation in the rat. | |
| US4999380A (en) | Treatment of lipoprotein disorders associated with cholesterol metabolism | |
| Koo et al. | Effect of marginal zinc deficiency on the morphological characteristics of intestinal nascent chylomicrons and distribution of soluble apoproteins of lymph chylomicrons | |
| AU611204B2 (en) | Treatment of lipoprotein disorders associated with cholesterol metabolism | |
| US20110207821A1 (en) | Method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosis | |
| Daher et al. | Effect of acute and chronic grapefruit, orange, and pineapple juice intake on blood lipid profile in normolipidemic rat. | |
| Tsai et al. | Mechanisms mediating lipoprotein responses to diets with medium-chain triglyceride and lauric acid | |
| Daher et al. | Effect of acute and chronic moderate alcohol consumption on fasted and postprandial lipemia in the rat | |
| da Silva Marineli et al. | Phytosterols: Biological effects and mechanisms of hypocholesterolemic action | |
| Kinsell et al. | Essential hyperlipemia | |
| Kahn et al. | A Study of the Hypocholesterolemic Activity of the Ethyl Esters of the Polyunsaturated Fatty Acids of Cod Liver Oil in the Chicken: II. Effect on Serum and Tissue Cholesterol and Aortic and Coronary Atherosclerosis | |
| WO2001068101A1 (en) | Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol | |
| Uza et al. | Serum zinc and copper in hyperlipoproteinemia | |
| Kritchevsky | Conjugated linoleic acid and experimental atherosclerosis in rabbits | |
| Baraona et al. | Alcoholic hyperlipemia |